MedPath
HSA Approval

DOXORUBICIN-TEVA CONCENTRATE FOR SOLUTION FOR INFUSION 2 MG/ML

SIN14969P

DOXORUBICIN-TEVA CONCENTRATE FOR SOLUTION FOR INFUSION 2 MG/ML

DOXORUBICIN-TEVA CONCENTRATE FOR SOLUTION FOR INFUSION 2 MG/ML

March 21, 2016

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Licence HolderTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, SOLUTION, CONCENTRATE

INTRAVENOUS, INTRAVESICAL

Medical Information

L01DB01

doxorubicin

Manufacturer Information

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

S.C. SINDAN-PHARMA S.R.L

Active Ingredients

Doxorubicin hydrochloride

2mg/ml

Doxorubicin

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

DOXORUBICIN-TEVA CONCENTRATE FOR SOLUTION FOR INFUSION 2 MG/ML - HSA Approval | MedPath